WO2025023901 - THE PHARMACEUTICAL COMBINATION COMPRISING PHOSPHODIESTERASE TYPE-5 INHIBITOR AND L-ARGININE
National phase entry is expected:
Publication Number
WO/2025/023901
Publication Date
30.01.2025
International Application No.
PCT/TR2023/050735
International Filing Date
26.07.2023
Title **
[English]
THE PHARMACEUTICAL COMBINATION COMPRISING PHOSPHODIESTERASE TYPE-5 INHIBITOR AND L-ARGININE
[French]
COMBINAISON PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE PHOSPHODIESTÉRASE DE TYPE 5 ET DE LA L-ARGININE
Applicants **
MONTERO GIDA SANAYI VE TICARET ANONIM SIRKETI
Inventors
PALANTOKEN, Arzu
TOMBAYOGLU, Vildan
TASKIN, Abdullah
OZTEKIN, Suat Hakan
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2000 | |
| EPO | Filing, Examination, Granting | 9177 | |
| Japan | Filing, Examination, Granting | 2130 | |
| South Korea | Filing, Examination, Granting | 1963 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,010
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a pharmaceutical combination comprising a PDE5 inhibitor and l-arginine.[French]
La présente invention concerne une combinaison pharmaceutique comprenant un inhibiteur de PDE5 et de la L-arginine.